A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : rVV / recombinant vaccinia virus

[Related PubMed/MEDLINE]
Total Number of Papers: 125
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   rVV  (>> Co-occurring Abbreviation)
Long Form:   recombinant vaccinia virus
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. HTLV-1, STLV-1
2015 Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection. EPX, RSV, Th
2014 Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. BAL, DCs, IL-2, SARS-CoV, TNF-alpha
2013 Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. KMP-11, VL
2013 Prime-boost vaccination with plasmid DNA followed by recombinant vaccinia virus expressing BgGARP induced a partial protective immunity to inhibit Babesia gibsoni proliferation in dogs. ---
2012 Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver. HCV
2012 Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. APC, ER, MHC, TAP
2012 [The development of therapeutic vaccine for hepatitis C virus]. HCV
2011 Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. CML, PR3, Tg
10  2011 Evaluating vaccinia virus cytokine co-expression in TLR GKO mice. ECTV, GKO, IFN, IL, NK, TLR
11  2010 Analysis of the mechanism by which BALB/c mice having prior immunization with nucleocapsid protein of SARS-CoV develop severe pneumonia after SARS-CoV infection. SARS, SARS-CoV
12  2010 Autoantigens plus interleukin-10 suppress diabetes autoimmunity. CTB, GAD, IL-10, NOD, T1DM
13  2010 Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. CTLs, i.n, ID, LDA, NCI, TAAs
14  2010 Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. CON-S
15  2010 [Construction of pSG5/TRIF and its expression in Huh7 cells]. ---
16  2009 Development of a cytotoxic T-cell assay in rabbits to evaluate early immune response to human T-lymphotropic virus type 1 infection. ATL, CTL, HTLV-1, SU, SV40
17  2009 Interleukin-15 mediates potent antiviral responses via an interferon-dependent mechanism. IFN, IL-15, NK
18  2008 Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. HCV
19  2007 Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. CTA, CTL, mAb, mDC, NSCLC
20  2006 An adaptation of recombinant vaccinia-based ELISPOT and intracellular cytokine staining for a comparative measurement of cellular immune responses in HIV-1 and HIV-2 infections in West Africa. HIV, ICA, IFN, PBMCs, SFC
21  2006 Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. ---
22  2006 Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epiotpe in NS3 region. CTL, HCV, PBMC
23  2006 Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses. CTB, GAD, IL, INS, NOD
24  2006 Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. CTLs, HIV, MALTs
25  2005 A vaccinia-based elispot assay for detection of CD8+ T cells from HIV-1 infected children. PBMC
26  2005 Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. DC, mDC, pDC, rAd, TAA
27  2005 IL-15-independent antiviral function of primary and memory CD8+ T cells. WT
28  2005 Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. APC, CD154, TAA, WT VV
29  2005 Protection of NOD mice from type 1 diabetes after oral inoculation with vaccinia viruses expressing adjuvanted islet autoantigens. CTB, INS, NOD
30  2005 Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. ---
31  2004 Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. DC, TAA
32  2004 Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Env, mV2, mV3, WT
33  2004 HIV type 1-specific inter- and intrasubtype cellular immune responses in HIV type 1-infected Ugandans. IFN-gamma
34  2004 Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model. ACC, Sp2-mStAR, StAR
35  2004 Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. B-LCL, CTL
36  2004 Vaccinia as a vector for gene delivery. ---
37  2003 Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Ags, DC, HLA, mDC, rVV-gp100
38  2003 Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. CT-SOD, SP-SOD
39  2003 Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. IFN-gamma, IL-4, VL
40  2003 Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes. BRSV, CTL, HRSV, IFN-gamma, MHC, rFPV
41  2003 Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma. i.t, s.c
42  2003 The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8+ T cell response in mice and is antigenic for PBMCs from HIV+ patients. ELISPOT, FWPV, HIV-1
43  2003 The transmembrane domain of vesicular stomatitis virus glycoprotein suffices to anchor HIV-1 envelope gp120 expressed by a recombinant vaccinia virus. aa, Env, VSV-G, VSVGTMCT
44  2002 Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. HAART, mDC, PBMC
45  2002 Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy. ---
46  2002 DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. NLS
47  2002 Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. CMI, CTL, HIV, PLG
48  2002 Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library. Ags, Env, GNA, HIV-1, OG
49  2002 Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. CTL, LCMV, TNF-alpha
50  2001 Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. IL, PFU
51  2001 Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth. Ig
52  2001 Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. DC, DC
53  2001 The export of major histocompatibility complex class I molecules from the endoplasmic reticulum of rat brown adipose cells is acutely stimulated by insulin. ER, HA, MHC-I
54  2000 Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. rBV, VLPs
55  2000 gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host. AL, BLV, PBM
56  2000 Interferon-inducible chemokines and immunity to poxvirus infections. EV, MIG
57  2000 Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. CMI, HIV-1, IL-12, NO
58  2000 Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. HDCV, IU
59  1999 Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. GCV
60  1999 Enhanced HIV-1 envelope-tumor protection by a recombinant vaccinia virus expressing anchored HIV-1 gp120 lacking gp41. HIV-1, PBS
61  1999 Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. IL-10
62  1999 Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. CTL, IL-4, RSV
63  1999 Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes. DC, EBV, ELISPOT
64  1999 Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. GG, mut p80
65  1999 Recombinant vaccinia viruses expressing an immunodominant epitope of HIV-1 envelope protein within an influenza hemagglutinin cassette predominantly prime epitope-specific CD8(+) CTL. CTL, HA, HIV-1
66  1998 An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence. HIV
67  1998 Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice. RPV
68  1998 Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. CTL
69  1998 Delivery of the Theileria parva p67 antigen to cattle using recombinant vaccinia virus: IL-2 enhances protection. ---
70  1998 Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. RSV
71  1998 Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. GCV, ORF
72  1998 gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. aa, MHC
73  1998 Immunizing effect of vaccinia virus expressing the nucleoprotein of rinderpest virus on systemic rinderpest virus infection in rabbits. NP, RPV
74  1998 P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells. ---
75  1998 Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. CTL, IgG1, IL-2, IL-4, RSV, TK
76  1998 Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. RSV
77  1997 Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. TAA
78  1997 Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+ lymphocytes in vitro. ---
79  1997 Chemical inactivation of recombinant vaccinia viruses and the effects on antigenicity and immunogenicity of recombinant simian immunodeficiency virus envelope glycoproteins. BEI, PFA, SIV-Env
80  1997 Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Ad2
81  1997 Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. mB7-1
82  1997 Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. ACV, GCV, HCMV, ORF, PCV, TK
83  1997 Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. BRSV
84  1997 Recombinant vaccinia viruses for the characterization of Plasmodium falciparum-specific cytotoxic T lymphocytes: recognition of processed antigen despite limited re-stimulation efficacy. CTL, LSA, TRAP
85  1997 [Interaction of gag polyprotein-precursors p55 and p48 with p160gag-pol during formation of virus-like particles of HIV-1 with recombinant strains of vaccinia virus]. ---
86  1996 Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. GM-CSF, IL-2
87  1996 Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. ---
88  1996 Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. ---
89  1996 IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. ---
90  1996 Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection. BEFV
91  1995 Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. RSV
92  1995 Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. FIV
93  1995 IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. TAA
94  1995 Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. ---
95  1994 Cytotoxic T lymphocyte responses to the envelope proteins of endogenous ecotropic and mink cytopathic focus-forming murine leukemia viruses in H-2b mice. MuLV
96  1994 Identification of cytotoxic T cell epitopes on the VP3 and VP6 rotavirus proteins. CTLs
97  1994 Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities. CTL, PBMC
98  1994 Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. BLV, CMI
99  1993 Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. RS
100  1993 Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein. CTLs